Oxidative Stress in Polycystic Ovary Syndrome

The aim of the study was to determine changes in hematological and biochemical parameters and specific oxidative stress markers in patients with PCOS.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Polycystic Ovarian Syndrome (PCOS) Adnexal Diseases Cysts Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Gonadal Disorders Neoplasms Ovarian Cysts Ovarian Diseases Oxidative Stress Polycystic Ovary Syndrome Urogenital Diseases

Age range

20 year–45 year

Sex eligibility

Female

Study type

Observational

Primary location

Alanya Training and Research Hospital Gynecology and Obstetrics Department

Antalya, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The PCOS group included patients with oligomenorrhea (menstrual period intervals of more than 35 days), clinical signs of hyperandrogenism (acne or hirsutism), biochemical signs of hyperandrogenism (with total testosterone of 100 ng/dL and above and patients with dehydroepiandrosterone sulfate of 400 g/dl and above), an LH/FSH ratio of over 3 on the second day of the menstrual period, a body mass index of 25 and above, and polycystic ovaries detected in suprapubic ultrasonography.

Exclusion criteria

Pregnant individuals, individuals with diabetes mellitus, metabolic syndrome, adrenal pathology, pelvic mass, and malignancy were not included in the study.

Treatment and study plan

Primary outcomes

Oxidative stress markers

Time frame: From January 2021 to December 2021

TAS, TOS, OSI, PON, ARES, total thiol, native thiol, disulfide (-S-S-), reduced thiol, oxidized thiol, and IMA

Sponsors and collaborators

Lead sponsor

Mardin Artuklu University

Other

Registry information

Official study title

Elucidation of the Oxidative Mechanism Effective in Polycystic Ovary Syndrome: a Randomized Controlled Clinical Study

Important dates

Study start: 2021
Primary completion: 2021
Study completion: 2025
First posted: Feb 14, 2025
Registry last updated: Feb 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed